3-(4-methoxyphenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-one | 41010-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-methoxyphenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-one
• 英文别名: 3-(4-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one；3-(4-methoxy-phenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one；3-(4-Methoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one；3-(4-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2-one
• CAS: 41010-72-4
• 化学式: C₁₃H₁₁N₃O₂
• mdl: MFCD28897380
• 分子量: 241.249
• InChiKey: YDFPOWYHKFYENI-UHFFFAOYSA-N

物化性质

• 熔点：
  255-257 °C(Solv: 1-propanol (71-23-8))
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-((4-甲氧基苯基)氨基)烟酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以101 mg的产率得到3-(4-methoxyphenyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-one
  参考文献：
  名称：

  WO2019198692A5

  摘要：

  公开号：

  WO2019198692A5

文献信息

• Synthesis of 1-and 3-substituted imidazo[4,5-b]pyridin-2-ones
  作者：Yu. M. Yutilov、N. N. Smolyar、D. A. Lomov

  DOI：10.1134/s1070428006060145

  日期：2006.6

  1- and 3-Substituted imidazo[4,5-b]pyridin-2-ones were synthesized by heating equimolar amounts of 3-amino-2-chloropyridine or 2-chloro-3-methylaminopyridine, urea, and the corresponding arylamine at 150-210 degrees C. The reaction of 3-amino-2-chloropyridine with urea and p-phenylenediamine or p,p'-diaminobiphenyl at a ratio of 2:2:1 under analogous conditions gave 1,4-bis-(2-oxoimidazo[4,5-b]pyridin-3-yl)benzene or 1,4-bis(2-oxoimidazo[4,5-b]pyridin-3-yl)biphenyl, respectively.
• FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
  申请人：RaQualia Pharma Inc.

  公开号：EP3774739B1

  公开（公告）日：2022-05-11
• [EN] FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST<br/>[FR] DÉRIVÉS D'URÉE CYCLIQUE FUSIONNÉS UTILISÉS COMME ANTAGONISTES DE CRHR2
  申请人：RAQUALIA PHARMA INC

  公开号：WO2019198692A1

  公开（公告）日：2019-10-17

  The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.
• WO2019198692A5
  申请人：——

  公开号：WO2019198692A5

  公开（公告）日：2023-05-19